Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Name Game: Will Innovators’ Latest Battlefront Kill Biosimilars?

This article was originally published in RPM Report

Executive Summary

Having lost the battle to prevent biosimilars reaching the market at all, innovators are now pushing for them to be stamped with unique international non-proprietary names. That could prove commercially fatal for copycat biologics.


Related Content

Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Track-and-Trace Bill Clears House With New Electronic Labeling Language
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem
Biosimilar Suffix Naming Idea Trips On Dispensing Problem


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts